Trademark: 79335933
Word
FEXUCLUE
Status
Registered
Status Code
700
Status Date
Tuesday, August 1, 2023
Serial Number
79335933
Registration Number
7123404
Registration Date
Tuesday, August 1, 2023
Mark Type
3000
Filing Date
Wednesday, January 19, 2022
Published for Opposition
Tuesday, May 16, 2023

Trademark Owner History
DAEWOONG PHARMACEUTICAL CO., LTD. - Original Registrant

Classifications
5 Pharmaceutical agents affecting digestive organs; medicines for treating intestinal disorders; Pharmaceutical preparations in the nature of proton-pump inhibitors for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; medicines for the treatment of gastrointestinal diseases; medicines for human purposes for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; pharmaceutical preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; ethical medicinal preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection
The mark consists of the stylized wording "FEXUCLUE" in blue, wherein the inside of the letter "C" is a design of the stomach in the colors red, orange, yellow and green. The color white in the mark is background only and is not claimed as a feature of the mark.
The color(s) the colors blue, green, red, orange, and yellow are claimed as features of the mark is/are claimed as a feature of the mark.

Trademark Events
Nov 27, 2023
Final Decision Transaction Processed By Ib
Nov 10, 2023
New Representative At Ib Received
Nov 2, 2023
Final Disposition Notice Sent To Ib
Nov 1, 2023
Final Disposition Processed
Nov 1, 2023
Final Disposition Notice Created, To Be Sent To Ib
Aug 1, 2023
Notice Of Registration Confirmation Emailed
Aug 1, 2023
Registered-Principal Register
May 17, 2023
Notification Processed By Ib
May 16, 2023
Official Gazette Publication Confirmation E-Mailed
May 16, 2023
Published For Opposition
Apr 26, 2023
Notification Of Possible Opposition Sent To Ib
Apr 26, 2023
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Apr 26, 2023
Notification Of Notice Of Publication E-Mailed
Apr 13, 2023
Approved For Pub - Principal Register
Mar 20, 2023
Teas/Email Correspondence Entered
Mar 17, 2023
Correspondence Received In Law Office
Mar 17, 2023
Teas Response To Office Action Received
Feb 1, 2023
Refusal Processed By Ib
Jan 12, 2023
Non-Final Action Mailed - Refusal Sent To Ib
Jan 12, 2023
Refusal Processed By Mpu
Nov 2, 2022
Non-Final Action (Ib Refusal) Prepared For Review
Nov 1, 2022
Non-Final Action Written
Oct 28, 2022
Assigned To Examiner
Mar 22, 2022
Application Filing Receipt Mailed
Mar 18, 2022
New Application Office Supplied Data Entered
Mar 17, 2022
Sn Assigned For Sect 66a Appl From Ib

Trademark Alertz updated from USPTO on 2030-01-24